Gastroparesis Treatment Market By Drug (Prokinetic Agents, Antiemetic), Disease Type (Diabetic Gastroparesis, Idiopathic Gastroparesis), By Route of Administration (Intravenous, Nasal), End-Users (Hospital Pharmacies, Retail Pharmacies), And Region for 2024-2031

Gastroparesis Treatment Market Valuation – 2024-2031

Increasing risk associated with other diseases, family history of diabetic gastroparesis, and genetic diseases are several factors propelling the global market for diabetic gastroparesis treatment. The market growth will be further stimulated by the increasing focus on targeted therapies and favorable government policies. This will lead to numerous opportunities for the growth of the market during the forecast period. Also, rapid urbanization, changing lifestyles, and an increase in the prevalence of frequent alcohol and tobacco use. Additionally, the launch of novel medications by the manufacturers is driving the market size to surpass USD 6213.42 Million in 2023 to reach a valuation of around USD 7905.21 Million by 2031.

Constant funding for R&D studies aimed at introducing new approaches to the current drug therapy for gastroparesis is anticipated to augment market growth. Increasing surgical procedures and the aging population are the main drivers propelling the gastroparesis medicine market to grow at a CAGR of 3.5% from 2024 to 2031.

Gastroparesis Treatment MarketDefinition/ Overview

Gastroparesis is a medical condition causing delayed stomach emptying due to impaired muscle motility or nerve dysfunction, resulting in food remaining in the stomach for an abnormally long period.

The Gastroparesis Treatment Market includes pharmaceuticals, medical devices, and therapies for managing and alleviating symptoms of delayed gastric emptying, caused by factors like diabetes, neurological disorders, or idiopathic reasons, aiming to improve gastric motility, reducing nausea and vomiting, and enhancing patient quality of life.

Gastric electrical stimulation devices are implanted in the abdomen to modulate gastric motility and alleviate symptoms of gastroparesis. These devices deliver electrical impulses to the stomach to improve gastric emptying. Therapeutic approaches for gastroparesis may include dietary modifications, such as eating smaller, more frequent meals or consuming liquid nutritional supplements. Behavioral therapies and counseling may also be beneficial in managing symptoms and improving patients’ overall well-being.

The focus is on personalized gastroparesis treatment, considering individual patient factors and disease severity. Digital health technologies, like smartphone applications and wearable devices, can help monitor symptoms remotely. Collaborative research between academia, industry, and healthcare organizations is expected to drive innovation and improve patient outcomes.

How will the Rise in R&D Investments Drive the Market of Gastroparesis Treatment?

Rising R&D investments enable pharmaceutical companies to innovate and develop new drugs, formulations, and treatment approaches for gastroparesis. Rising R&D investments enable pharmaceutical companies to innovate and develop new drugs, formulations, and treatment approaches for gastroparesis. By introducing innovative therapies and maintaining a robust pipeline of novel drugs, these manufacturers can differentiate themselves from competitors and capture a larger share of the Gastroparesis Treatment Market.

The rising incidence of diabetes means a larger pool of patients at risk of developing diabetic gastroparesis. This expanding patient pool presents a substantial market opportunity for pharmaceutical companies, medical device manufacturers, and healthcare providers offering gastroparesis treatments.

Also, the growth in diabetic gastroparesis cases spurs innovation in treatment modalities, including developing novel drugs, minimally invasive medical devices, and advanced therapeutic approaches tailored to the specific needs of gastroparesis patients. These technological advancements contribute to the expansion and diversification of the Gastroparesis Treatment Market.

Rising rates of regular alcohol and tobacco consumption coupled with an aging population can influence the Gastroparesis Treatment Market by increasing the incidence of gastroparesis, driving demand for effective treatments, presenting challenges in disease management, focusing on prevention and education, and necessitating tailored treatment approaches.

Will Costs and Side Effects of Gastroparesis Treatment Restrain Its Market?

Advanced treatment modalities for gastroparesis, such as gastric electrical stimulation devices or minimally invasive surgical procedures, often come with substantial costs. These costs can make these treatments inaccessible to patients without adequate insurance coverage or financial resources. As a result, a significant portion of the patient population may be unable to afford these advanced therapies, limiting their adoption and impeding market growth.

Increasing incidence of serious side effects associated with gastroparesis drugs may raise concerns about patient safety. Regulatory agencies closely monitor the safety profile of approved medications. They may impose restrictions or warnings based on emerging safety data. Public awareness of safety issues can undermine confidence in certain drugs and dampen market growth by reducing patient and physician acceptance of these treatments.

The regulatory approval process for new gastroparesis drugs can be lengthy and complex. Pharmaceutical companies must conduct extensive preclinical and clinical trials to demonstrate the safety and efficacy of their products, which can take several years and involve significant financial investments. Delays or setbacks in the regulatory approval process can hinder the timely introduction of new treatments to the market, slowing down market growth.

Category-Wise Acumens

How will the Increasing Prevalence of Diabetic Gastroparesis Drive the Growth of the Market?

The diabetic gastroparesis segment is anticipated to hold a major share of the Gastroparesis Treatment Market. Diabetic gastroparesis (DGp) is a neuropathy disorder caused by poorly managed type 1 and type 2 diabetes, ruled out by diagnostic workups, excluding obstruction and potential gastric emptying drugs.

Increasing diabetes mellitus population worldwide enables a high demand for diabetic gastroparesis drugs. According to the data published in September 2021, it is estimated that around 537 million adults will be living with diabetes in 2021. Additionally, the total number of people with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. It is also estimated that 3 out of 4 adults with diabetes will be living in low- and middle-income countries in 2021. Pharmaceutical companies and researchers are developing drugs for diabetic gastroparesis, driving market growth. Processa Pharmaceuticals initiated a Phase 2A trial for PCS12852, a potential gastroparesis treatment.

Government initiatives aimed at addressing the rising prevalence of diabetes and its complications can indirectly support the Gastroparesis Treatment Market. Policies focused on improving diabetes management, enhancing access to healthcare services, and promoting research and development in gastroenterology can create a conducive environment for market growth.

Incentives such as research grants, regulatory support, and public health campaigns further drive investment in diabetic gastroparesis treatment. Therefore, with the increasing prevalence of diabetes, diabetic gastroparesis is also expected to increase, thus leading to segment growth.

Which Factors Enhance the Use of Prokinetic Agents in Gastroparesis Treatment?

The prokinetic agents segment dominated the market owing to the effectiveness and safety of the drugs that come into this category. Prokinetic agents are a type of medication that increases the contractions of stomach muscles, which helps to improve the overall movement of the stomach. These drugs are often prescribed to patients who are suffering from gastroparesis, a condition that causes symptoms such as nausea and vomiting and hinders digestion.

Prokinetic agents are considered a cornerstone in the treatment of gastroparesis because they address the underlying issue behind the condition. In addition to their role in treating gastroparesis, these drugs have also been studied for their efficiency and safety in critically ill patients receiving enteral nutrition. The results have shown that they are effective in reducing feeding intolerance among such patients.

Also, prokinetic agents can provide effective symptom relief in patients with gastroparesis by reducing the frequency and severity of gastrointestinal symptoms. This includes alleviating nausea, vomiting, abdominal discomfort, and postprandial fullness, which are common manifestations of delayed gastric emptying in gastroparesis patients, thus leading to segment growth.

Gain Access to Gastroparesis Treatment Market Report Methodology

Country/Region-wise Acumens

Will Advanced Healthcare Infrastructure in North America Mature Gastroparesis Treatment Market?

North America is expected to lead the gastroparesis medicine market due to its aging population and an increase in surgical treatments. The United States is at the forefront of the market, primarily because of its large population with diabetes, favorable reimbursement policies, and increased awareness of the ailment. In June 2022, the reported that 96 million adults in the US have prediabetes, accounting for 38.0% of the adult population. The region’s dominance in the industry is due to a rise in healthcare expenditure, a growing hospital population, and well-established infrastructure.

The North American region boasts of an advanced healthcare infrastructure and robust research and development initiatives that foster innovation in treatment options. The well-developed reimbursement systems and insurance coverage in the region also enhance patient access to treatment, leading to an increase in market demand.

Moreover, there is a high prevalence of gastroparesis cases in North America, which is often associated with conditions such as diabetes and post-surgical complications, thereby driving the demand for effective therapies. The growing aging population, which is prone to gastroparesis, coupled with an increasing focus on healthcare technologies, contributes to North America’s dominant position in the Gastroparesis Treatment Market. As a result, it continues to lead in terms of market size and influence.

Will Rising Industrialization Enhance Adoption of Gastroparesis Treatment in Asia Pacific?

Rising urbanization and economic expansion in the Asia Pacific region drive the market for gastroparesis treatment by improving healthcare infrastructure, increasing the prevalence of chronic diseases, boosting healthcare spending, and fostering technological advancements and innovation. These factors create a conducive environment for market growth.

Economic growth plays a crucial role in fostering technological advancements and innovation in healthcare. This leads to the development of new diagnostic tools, treatment modalities, and therapeutic approaches for gastroparesis. Healthcare providers in urban areas are fortunate enough to have access to cutting-edge medical technologies and state-of-the-art treatment options. This improved access to healthcare leads to better outcomes for patients and drives market expansion.

Moreover, economic prosperity attracts investments in research and development, leading to the introduction of novel drugs and devices for gastroparesis treatment in the Asia Pacific market.

Competitive Landscape

The competitive landscape of the Gastroparesis Treatment Market is fragmented, with a mix of established players and emerging companies developing novel therapies. Major players focus on medications (prokinetics, antiemetics), while others are involved in medical devices (gastric electric stimulation) and nutritional support methods.

The organizations are focusing on. Rising research and development efforts aim to address the limitations of existing treatments and introduce new options. Some of the prominent players operating in the Gastroparesis Treatment Market include

Evoke Pharma, AstraZeneca, Cadila Pharmaceuticals, Neurogastrx, Inc., AbbVie Inc. (Allergan Plc), Marel, Formax, Weber, Devro, Tipper Tie, Handtmann, Middleby Corporation, GEA Group, Evoke Pharma, R. Bard, Inc., Rhythm Pharmaceuticals, Inc., Boston Scientific Corporation, Kimberly-Clark Corporation, Vanda Pharmaceuticals.

Latest Developments

• In March 2021, Johns Hopkins Medicine conducted a clinical trial on Gastric per-oral Endoscopic Myotomy to treat and manage refractory gastroparesis. The G-POEM treatment was shown to be safe, with modest effectiveness in treating refractory gastroparesis.
• In December 2022, The Mayo Clinic, a US-based academic medical facility, conducted a clinical trial on Rifaximin to treat diabetic gastroparesis.
• In February 2022, Vanda Pharmaceuticals Inc. (Vanda) announced Phase Ill clinical trial results for VP-VLY-686-3303, demonstrating the efficacy and safety of precipitant in treating gastroparesis symptoms.

Report Scope

Gastroparesis Treatment Market, By Category

Drug

• Prokinetic Agents
• Antiemetic
• Botulinum Toxin Injections
• Nutritional Support

Disease Type

• Diabetic gastroparesis
• Idiopathic gastroparesis
• Post-surgical gastroparesis

Route Of Administration

• Intravenous
• Nasal
• Oral

End-Users

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Region

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.